IRIS
BALESTRIERI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.660
NA - Nord America 1.003
EU - Europa 365
SA - Sud America 215
Continente sconosciuto - Info sul continente non disponibili 53
AF - Africa 23
OC - Oceania 3
Totale 3.322
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 994
US - Stati Uniti d'America 932
CN - Cina 256
IT - Italia 190
BR - Brasile 155
VN - Vietnam 138
HK - Hong Kong 113
BD - Bangladesh 71
FR - Francia 45
GB - Regno Unito 42
DE - Germania 28
MX - Messico 26
CA - Canada 25
AR - Argentina 19
IN - India 17
EC - Ecuador 14
NL - Olanda 13
ID - Indonesia 12
RU - Federazione Russa 10
CO - Colombia 9
PL - Polonia 7
ZA - Sudafrica 7
JP - Giappone 6
PK - Pakistan 6
UA - Ucraina 6
ES - Italia 5
IQ - Iraq 5
MY - Malesia 5
PH - Filippine 5
TR - Turchia 5
VE - Venezuela 5
CR - Costa Rica 4
IR - Iran 4
PE - Perù 4
PY - Paraguay 4
SA - Arabia Saudita 4
TN - Tunisia 4
AU - Australia 3
AZ - Azerbaigian 3
CL - Cile 3
CZ - Repubblica Ceca 3
HN - Honduras 3
KZ - Kazakistan 3
SE - Svezia 3
UZ - Uzbekistan 3
AM - Armenia 2
AT - Austria 2
BB - Barbados 2
BO - Bolivia 2
BW - Botswana 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ET - Etiopia 2
FI - Finlandia 2
GT - Guatemala 2
JO - Giordania 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
SI - Slovenia 2
BS - Bahamas 1
CG - Congo 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
GE - Georgia 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
ME - Montenegro 1
MG - Madagascar 1
MQ - Martinica 1
NI - Nicaragua 1
RO - Romania 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VC - Saint Vincent e Grenadine 1
Totale 3.270
Salva come PNG Salva come JPEG
Città #
San Jose 235
Ashburn 213
Singapore 186
Hong Kong 108
Rome 107
Beijing 86
Hefei 68
Council Bluffs 54
Ho Chi Minh City 51
Columbus 43
Lauterbourg 38
Boardman 35
Hanoi 35
Dallas 30
London 30
Phoenix 28
Shanghai 22
Santa Clara 20
Los Angeles 16
Mexico City 15
New York 15
São Paulo 14
Amsterdam 7
Brooklyn 7
Chicago 7
Munich 7
Warsaw 7
Milan 6
Nuremberg 6
Quito 6
Rio de Janeiro 6
San Francisco 6
Seattle 6
Toronto 6
Buffalo 5
Tokyo 5
Atlanta 4
Boydton 4
Brasília 4
Buenos Aires 4
Catania 4
Charlotte 4
Da Nang 4
Kuala Lumpur 4
Orem 4
Pune 4
Turin 4
Bauru 3
Biên Hòa 3
Bắc Giang 3
Cagliari 3
Dhaka 3
Guarulhos 3
Hamburg 3
Johannesburg 3
Las Vegas 3
Lima 3
Limeira 3
Markham 3
Medellín 3
Naples 3
Paris 3
Philadelphia 3
Queens 3
Stockholm 3
Amman 2
Apodaca 2
Asunción 2
Atibaia 2
Baghdad 2
Baku 2
Banī Suwayf 2
Bari 2
Barquisimeto 2
Berlin 2
Bogotá 2
Boston 2
Bridgetown 2
Brno 2
Bắc Ninh 2
Canberra 2
Canela 2
Caracas 2
Caxias do Sul 2
Chennai 2
Cotia 2
Curitiba 2
Dagenham 2
Formosa 2
Frankfurt am Main 2
Guiyang 2
Haiphong 2
Hewitt 2
Hưng Yên 2
Itapevi 2
Jeddah 2
La Paz 2
Liverpool 2
Ljubljana 2
Louisville 2
Totale 1.704
Salva come PNG Salva come JPEG
Nome #
Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients 246
Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus 234
Acid reflux episodes sensitize the esophagus to perception of weakly acidic and mixed reflux in non-erosive reflux disease patients 144
Wall Thickness Ratio—A New Magnetic Resonance Parameter—Is Associated With the Outcome of Biological Therapy in Patients With Ileal and Ileocolonic Crohn’s Disease 143
Mathematical Modeling of Vedolizumab Treatment’s Effect on Microbiota and Intestinal Permeability in Inflammatory Bowel Disease Patients 128
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease 111
Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients 110
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC) 96
Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults 93
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study 85
Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study 80
Psychological distress in inflammatory bowel disease 80
Impedance-High Resolution Manometry Analysis of Patients With Nonerosive Reflux Disease 79
Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases 78
Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy 78
Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. 75
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 72
The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough 72
Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease 71
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy 67
Vedolizumab in inflammatory bowel disease: Real-world outcomes and their prediction with machine learning—the IG-IBD LIVE study 65
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 65
Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study 64
Ultrasonography Tight Control and Monitoring in Crohn’s Disease During Different Biological Therapies: A Multicenter Study 61
Adalimumab in active ulcerative colitis: A "real-life" observational study 60
Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responder to proton pump inhibitors 59
Therapeutic adherence in inflammatory bowel disease: User guide from a multidisciplinary modified Delphi consensus 55
Intra-bolus pressure and esophagogastric gradient, assessed with high-resolution manometry, are associated with acid exposure and proximal migration of refluxate 55
Weak peristalsis with large breaks is associated with higher acid exposure and delayed reflux clearance in the supine position in GERD patients 54
High-resolution Manometry Findings During Solid Swallows Correlate With Delayed Reflux Clearance and Acid Exposure Time in Non-erosive Reflux Disease Patients 53
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 52
Nutritional aspects in inflammatory bowel diseases 52
Role of Esophageal Motility, Acid Reflux, and of Acid Suppression in Nonobstructive Dysphagia 52
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS‐CoV‐2 infection: an IG‐IBD study 50
IBD Flare in the COVID-19 Pandemic: Therapy Discontinuation Is to Blame 49
Reflux Patterns and Role of Impedance-pH Variables in Predicting PPI Response in Patients With Suspected GERD-Related Chronic Cough 48
Role of Overweight and Obesity in Gastrointestinal Disease 47
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 43
Role of Mixed Reflux and Hypomotility with Delayed Reflux Clearance in Patients with Non-cardiac Chest Pain 43
Understanding the relationship between esophageal motor disorders and reflux disease 41
REFLUX PATTERN AND ROLE OF IMPEDANCE-PH VARIABLES IN PREDICTING PPI RESPONSE IN PATIENTS WITH SUSPECTED GERD-RELATED CHRONIC COUGH 40
Therapeutic drug monitoring is more cost-effective than a clinically based approach in the management of loss of response to infliximab in inflammatory bowel disease: An observational multicentre study 37
Patients With Extra-Esophageal Symptoms, Compared to NERD Patients With Typical Symptoms and Healthy Volunteers, Arc Characterized by a Higher Number of Reflux Episodes and Higher Proportion of Weakly Acidic and Mixed Reflux 35
Totale 3.322
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.890
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.890
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202228 0 0 0 0 0 0 0 0 0 0 0 28
2022/202310 0 0 0 0 1 0 0 0 1 0 8 0
2023/202494 4 11 3 5 6 37 3 6 0 7 9 3
2024/20251.031 22 8 37 3 11 23 23 3 72 71 301 457
2025/20261.789 159 116 173 272 80 74 345 98 165 133 85 89
2026/2027366 29 138 99 100 0 0 0 0 0 0 0 0
Totale 3.322